Advertisement

Mastocytosis pp 287-299 | Cite as

History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis

  • Peter ValentEmail author
  • Michel Arock
  • Emir Hadzijusufovic
  • Wolfgang R. Sperr
  • Karin Hartmann
  • Cem Akin
  • Dean D. Metcalfe
  • Hans-Peter Horny
Chapter
First Online:

Abstract

Mastocytosis is a unique and rare hematologic neoplasm characterized by abnormal expansion and accumulation of tissue mast cells in various organ systems. The clinical course and prognosis vary among patients, depending on the category of disease, comorbidities, and patient-related features. The cutaneous lesions of mastocytosis were first described by Nettleship and Tay in 1869. In the twentieth century, systemic forms of mastocytosis were identified and grouped into indolent and aggressive (advanced) variants. Between 1990 and 2000, diagnostic criteria and a classification of mastocytosis were established by an EU/US consensus group, and this classification was adopted by the World Health Organization (WHO) in 2001. In 2002, the European Competence Network on Mastocytosis (ECNM) was inaugurated and started. Expert representatives of this network and the consensus group served as major participants and advocates of mastocytosis research in Europe and in the USA over the past 20 years. Their achievements and the resulting clinical concepts and guidelines are summarized in the present article.

Keywords

Mastocytosis Mast cell leukemia Tryptase KIT ECNM Prognostication 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology. 1979;3:349–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96:2S–4S.PubMedCrossRefGoogle Scholar
  3. 3.
    Austen KF. Systemic Mastocytosis. N Engl J Med. 1992;326:639–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr. 1996;108:385–97.PubMedGoogle Scholar
  5. 5.
    Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122:1–23.CrossRefGoogle Scholar
  7. 7.
    Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114:3–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74:121–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112:946–56.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3:497–516.PubMedCrossRefGoogle Scholar
  11. 11.
    Valent P, Horny H-P, Escribano L, Longley JB, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Report of ‘Year 2000 Working Conference on Mastocytosis’. Leuk Res. 2001;25:603–25.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, Bennett JM. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Mastocytosis. World Health Organization (WHO) classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 291–302.Google Scholar
  13. 13.
    Horny HP, Akin C, Metcalfe DD, Bain BJ, Akin C, Escribano L, et al. Mastocytosis (mast cell disease). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization (WHO) classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 54–63.Google Scholar
  14. 14.
    Horny HP, Akin C, Arber DA, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon; 2017. p. 62–9.Google Scholar
  15. 15.
    Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol. 2002;127:140–2.PubMedCrossRefGoogle Scholar
  16. 16.
    Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57:604–8.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–36.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Pardanani A, Lim KH, Lasho TL, Finke CM, McClure RF, Li CY, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115:150–1.CrossRefPubMedGoogle Scholar
  19. 19.
    Sperr WR, Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol. 2012;5:261–74.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127:147–52.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Hartmann K, Henz BM. Cutaneous mastocytosis – clinical heterogeneity. Int Arch Allergy Immunol. 2002;127:143–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123:680–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Investig. 2007;37:435–53.CrossRefGoogle Scholar
  25. 25.
    Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099–104.e4.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215–25.CrossRefPubMedGoogle Scholar
  27. 27.
    Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013;68:417–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Sokol H, Georgin-Lavialle S, Grandpeix-Guyodo C, Canioni D, Barete S, Dubreuil P, et al. Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflamm Bowel Dis. 2010;16:1247–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Rossini M, Zanotti R, Viapiana O, Tripi G, Orsolini G, Idolazzi L, et al. Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin N Am. 2014;34:383–96.CrossRefGoogle Scholar
  30. 30.
    Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Ustun C, Arock M, Kluin-Nelemans HC, Reiter A, Sperr WR, George T, et al. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016;101:1133–43.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of Mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77:1261–70.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Nettleship E, Tay W. Rare forms of urticaria. Brit Med J. 1869;2:323–30.CrossRefGoogle Scholar
  34. 34.
    Ehrlich P. Beiträge zur Kenntniss der granulirten Bindegewebszellen und der eosinophilen Leukocythen. Arch Anat Physiol. 1879:166–9.Google Scholar
  35. 35.
    Unna PG. Anatomie und pathogenese der urticaria simplex und pigmentosa. Monatschr Prakt Dermatol. 1887;6:EH1.Google Scholar
  36. 36.
    Ellis JM. Urticaria pigmentosa. A report of a case with autopsy. AMA Arch Pathol. 1949;48:426–9.Google Scholar
  37. 37.
    Efrati P, Klajman A, Spitz H. Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations. Blood. 1957;12:869–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Friedman BI, Will JJ, Freiman DG, Braunstein H. Tissue mast cell leukemia. Blood. 1958;13:70–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore). 1988;67:345–68.CrossRefGoogle Scholar
  40. 40.
    Kitamura Y, Go S, Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood. 1978;52:447–52.PubMedCrossRefGoogle Scholar
  41. 41.
    Kitamura Y, Matsuda H, Hatanaka K. Clonal nature of mast-cell clusters formed in W/Wv mice after bone marrow transplantation. Nature. 1979;281:154–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Kitamura Y, Yokoyama M, Matsuda H, Ohno T, Mori KJ. Spleen colony-forming cell as common precursor for tissue mast cells and granulocytes. Nature. 1981;291:159–60.PubMedCrossRefGoogle Scholar
  43. 43.
    Födinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H, et al. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood. 1994;84:2954–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K, Bettelheim P. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood. 1989 May 15;73(7):1778–85.PubMedCrossRefGoogle Scholar
  45. 45.
    Agis H, Füreder W, Bankl HC, Kundi M, Sperr WR, Willheim M, et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology. 1996;87:535–43.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Horny HP, Ruck P, Xiao JC, Kaiserling E. Immunoreactivity of normal and neoplastic human tissue mast cells with macrophage-associated antibodies, with special reference to the recently developed monoclonal antibody PG-M1. Hum Pathol. 1993;24:355–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Agis H, Willheim M, Sperr WR, Wilfing A, Krömer E, Kabrna E, et al. Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J Immunol. 1993;151:4221–7.PubMedGoogle Scholar
  48. 48.
    Kempuraj D, Saito H, Kaneko A, Fukagawa K, Nakayama M, Toru H, et al. Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood. 1999;93:3338–46.PubMedCrossRefGoogle Scholar
  49. 49.
    Kocabas CN, Yavuz AS, Lipsky PE, Metcalfe DD, Akin C. Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature. J Allergy Clin Immunol. 2005;115:1155–61.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol. 1992;52:333–423.PubMedCrossRefGoogle Scholar
  51. 51.
    Parwaresch MR, Horny HP, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract. 1985;179:439–61.PubMedCrossRefGoogle Scholar
  52. 52.
    Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol. 1990;76:186–93.PubMedCrossRefGoogle Scholar
  53. 53.
    Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32:3264–74.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 1995;96:2702–10.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560–4.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12:312–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Escribano L, Orfao A, Díaz-Agustin B, Villarrubia J, Cerveró C, López A, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998;22:1132–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, Valent P. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25:529–36.CrossRefPubMedGoogle Scholar
  60. 60.
    Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113:357–64.PubMedCrossRefGoogle Scholar
  61. 61.
    Valent P, Escribano L, Parwaresch RM, Schemmel V, Schwartz LB, Sotlar K, et al. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol. 1999;120:1–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Valent P, Arock M, Bischoff SC, Bühring HJ, Brockow K, Escribano L, et al. The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr. 2004;116:647–51.PubMedCrossRefGoogle Scholar
  63. 63.
    The European Competence Network on Mastocytosis – ECNM: homepage on web-link: http://www.ecnm.net.
  64. 64.
    Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, et al. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012;124:807–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Peter Valent
    • 1
    • 2
    Email author
  • Michel Arock
    • 3
  • Emir Hadzijusufovic
    • 1
    • 2
    • 4
  • Wolfgang R. Sperr
    • 1
    • 2
  • Karin Hartmann
    • 5
  • Cem Akin
    • 6
  • Dean D. Metcalfe
    • 7
  • Hans-Peter Horny
    • 8
  1. 1.Department of Internal Medicine I, Division of Hematology & HemostaseologyMedical University of ViennaViennaAustria
  2. 2.Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of ViennaViennaAustria
  3. 3.Cellular and Molecular Oncology, LBPA CNRS UMR8113, Ecole Normale Superiéure de Paris SaclayCachanFrance
  4. 4.Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical Unit of Internal MedicineUniversity of Veterinary Medicine ViennaViennaAustria
  5. 5.Division of Allergy, Department of DermatologyUniversity of BaselBaselSwitzerland
  6. 6.Professor of Medicine, Division of Allergy and Clinical ImmunologyUniversity of MichiganAnn ArborUSA
  7. 7.Laboratory of Allergic Diseases, NIAID, NIHBethesdaUSA
  8. 8.Institute of Pathology, Ludwig Maximilian UniversityMunichGermany

Personalised recommendations

Cite chapter

Buy options